Results of MAIC study comparing pirtobrutinib ... - CLL Support
Results of MAIC study comparing pirtobrutinib vs venetoclax in CLL patients previously treated with a covalent BTK inhibitor
You need to be a member of this community to see this post.
Read more about...
7 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
Pirtobrutinib is the first FDA approved non-covalent BTK inhibitor (BTKi) for the treatment of CLL....
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in
LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase. Phase 1 trial results.
Rocbrutinib is a new drug offering hope to patients with what are known as gatekeeper mutations...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Good News! BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
3rd April 2020 Blood
Key points to note:
BTK inhibitor therapy achieves durable disease...
Related Posts
- Encouraging results from venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
- VenR in Relapsed CLL: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from MURANO 3 study
- BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Role of RITUXIMAB in CLL treatment in combination with Venetoclax
Comparative analysis of targeted novel therapies (ibrutinib vs. venetoclax) in relapsed, refractory CLL (Feb 2020)
